Oxford Drug Design Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$4.6M
- Investors
-
18
Oxford Drug Design General Information
Description
Operator of a biotechnology company intended to develop therapies to treat drug-resistant infections. The company's methods offer the application of new technologies to drive computer-aided drug discovery from target identification through preclinical and formulation studies and against cancer and other challenging diseases with high unmet medical needs seeking good patient outcomes, enabling healthcare professionals to access new antibiotics to treat drug-resistant bacterial infections.
Contact Information
Website
www.oxforddrugdesign.comCorporate Office
- Oxford Centre For Innovation
- New Road
- Oxford OX1 1BY
- England, United Kingdom
Corporate Office
- Oxford Centre For Innovation
- New Road
- Oxford OX1 1BY
- England, United Kingdom
Oxford Drug Design Timeline
Oxford Drug Design Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Equity Crowdfunding | $4.6M | Completed | Generating Revenue | |||
| 15. Later Stage VC | 01-Feb-2024 | Completed | Generating Revenue | |||
| 14. Later Stage VC | 19-May-2022 | Completed | Generating Revenue | |||
| 13. Grant | 01-Dec-2021 | Completed | Generating Revenue | |||
| 12. Grant | 01-Jun-2020 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series A) | 30-Jun-2019 | Completed | Generating Revenue | |||
| 10. Grant | 01-Jun-2019 | Completed | Generating Revenue | |||
| 9. Grant | 01-Jan-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 30-Nov-2017 | $2.02M | $5.5M | Completed | Generating Revenue | |
| 7. Grant | 10-Oct-2017 | $4.03M | $3.48M | Completed | Generating Revenue |
Oxford Drug Design Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Preferred | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 32,067 | $0.012515 | $36.97 | $36.97 | 1x | $36.97 | 0.04% | |
| Ordinary | 18,641 | $0.012515 | $33.9 | $33.9 | 1x | $33.9 | 0.02% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Oxford Drug Design Comparisons
Industry
Financing
Details
Oxford Drug Design Competitors (13)
One of Oxford Drug Design’s 13 competitors is Verge Genomics, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verge Genomics | Venture Capital-Backed | South San Francisco, CA | ||||
| Pragma Bio | Venture Capital-Backed | South San Francisco, CA | ||||
| Adapsyn | Venture Capital-Backed | Hamilton, Canada | ||||
| Atomwise | Venture Capital-Backed | San Francisco, CA | ||||
| Arctoris | Venture Capital-Backed | Abingdon, United Kingdom |
Oxford Drug Design Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oxford Drug Design Patents
Oxford Drug Design Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020409713-A1 | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Pending | 19-Dec-2019 | ||
| CA-3157947-A1 | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Pending | 19-Dec-2019 | ||
| EP-4077289-A1 | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Pending | 19-Dec-2019 | ||
| US-12247004-B2 | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Active | 19-Dec-2019 | ||
| US-20230114875-A1 | 2-amino-n-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Active | 19-Dec-2019 | C07D277/16 |
Oxford Drug Design Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oxford Drug Design Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cambridge Angels | Angel Group | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| SyndicateRoom | Venture Capital | Minority | ||
| ACF Investors | Angel Group | Minority | ||
| R42 Group | Venture Capital | Minority |
Oxford Drug Design FAQs
-
When was Oxford Drug Design founded?
Oxford Drug Design was founded in 2001.
-
Where is Oxford Drug Design headquartered?
Oxford Drug Design is headquartered in Oxford, United Kingdom.
-
What is the size of Oxford Drug Design?
Oxford Drug Design has 10 total employees.
-
What industry is Oxford Drug Design in?
Oxford Drug Design’s primary industry is Drug Discovery.
-
Is Oxford Drug Design a private or public company?
Oxford Drug Design is a Private company.
-
What is the current valuation of Oxford Drug Design?
The current valuation of Oxford Drug Design is .
-
What is Oxford Drug Design’s current revenue?
The current revenue for Oxford Drug Design is .
-
How much funding has Oxford Drug Design raised over time?
Oxford Drug Design has raised $15.6M.
-
Who are Oxford Drug Design’s investors?
Cambridge Angels, Meltwind Advisory, SyndicateRoom, ACF Investors, and R42 Group are 5 of 18 investors who have invested in Oxford Drug Design.
-
Who are Oxford Drug Design’s competitors?
Verge Genomics, Pragma Bio, Adapsyn, Atomwise, and Arctoris are some of the 13 competitors of Oxford Drug Design.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
